Trial Profile
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Onartuzumab (Primary) ; Bevacizumab; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 28 Apr 2020 Results (n=1427) assessing the prognostic value of the T effector RNA gene signature (Teff) in four studies (BO20289, NO17629, GO25632 and OAM4861G), presented at the 111th Annual Meeting of the American Association for Cancer Research - I.
- 04 May 2016 Status changed from active, no longer recruiting to completed.
- 22 Jul 2015 Primary endpoint (Progression-free survival duration) has not been met, according to a results published in the Annals of Oncology journal.